Privately-held Breath Therapeutics said today that it kicked off a Phase III clinical program for its liposomal formulation of cyclosporine A for the treatment of bronchiolitis obliterans syndrome. The company’s primary drug candidate, L-CsA-i, is an inhaled therapy delivered via Pari Pharma‘s investigational eFlow nebulizer. The Boston-1 trial is slated to enroll people with BOS […]
Pari Pharma lands FDA nod for Lamira nebulizer
Pari Pharma said this week that its Lamira nebulizer won approval from the FDA to deliver Insmed’s Arikayce amikacin liposome inhalation suspension for the treatment of MAC lung disease. The company’s Lamira drug-device combination product is intended to be used as part of a combination antibacterial drug regimen for adult patients with limited or no […]
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn